Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04919811 · ClinicalTrials.gov registry record · Phase 2
Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC
A Phase 2 study of Non-Small Cell Lung Cancer, sponsored by Nuvation Bio.
- Active
- Registry status
- Phase 2
- Development phase
- 217
- Enrollment target
- 20
- Study locations
NCT04919811 is a Phase 2 study of Non-Small Cell Lung Cancer that is active but no longer recruiting, run by Nuvation Bio. The registered enrollment target is 217 participants, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (67% lower). The trial reports 20 study locations across 9 states.
The verdict
NCT04919811, a Phase 2 study of Non-Small Cell Lung Cancer, is active but no longer recruiting, sponsored by Nuvation Bio.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 217 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of the study is to evaluate safety and efficacy of taletrectinib (also known as AB-106 or DS-6051b) monotherapy in the treatment of advanced NSCLC.
Conditions Studied
Interventions
- DRUG Taletrectinib
Study Locations (20)
California
- Beverly Hills Cancer Center - Beverly Hills
- The Oncology Institute of Hope and Innovation - Glendale
- Moores Cancer Center at UC San Diego - La Jolla
- Keck Medicine of University of Southern California - Los Angeles
- UCI Medical Center - Orange
- Ventura County Hematology-Oncology Specialists - Oxnard
Florida
- SCRI - Florida Cancer Specialists South - Fort Meyers
- Memorial Cancer Institute at Memorial Hospital East - Hollywood
- Cancer Specialists of North Florida - Jacksonville
- Memorial Cancer Institute at Memorial Hospital West - Pembroke Pines
Texas
- Texas Oncology, P.A. - Dallas
- Renovatio Clinical - El Paso
- MD Anderson Cancer Center - Houston
- Renovatio Clinical - The Woodlands
Louisiana
- SCRI - Hematology Oncology Clinic - Baton Rouge
Minnesota
- Mayo Clinic - Rochester
New Jersey
- Center for Cancer Research - Brick
Ohio
- Cleveland Clinic Foundation - Cleveland
Tennessee
- SCRI - Tennessee Oncology - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 217 participants |
| Start Date | 2021-09-01 |
| Est. Completion | 2027-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04919811
The ClinicalTrials.gov registry entry for NCT04919811 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 217 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (67% lower). The listed sponsor is Nuvation Bio, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Taletrectinib is the first listed.
NCT04919811 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT04919811 about?
NCT04919811 is a clinical study titled "Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC". The main purpose of the study is to evaluate safety and efficacy of taletrectinib (also known as AB-106 or DS-6051b) monotherapy in the treatment of advanced NSCLC.
What is the current status of trial NCT04919811?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 217 participants. The study started on 2021-09-01. Estimated completion is 2027-12.
What conditions does trial NCT04919811 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT04919811?
The interventions under investigation include: Taletrectinib (DRUG).
Who is sponsoring clinical trial NCT04919811?
This trial is sponsored by Nuvation Bio, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04919811 being conducted?
This trial has 20 study locations across California, Florida, Louisiana, Minnesota, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RECRUITING · Phase 2
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.